Biodesix Using VeriStrat to Evaluate Kadmon's Tyrosine Kinase Inhibitor | GenomeWeb

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Biodesix today announced it is collaborating with biopharma Kadmon to evaluate the use of Biodesix's test for a non-small cell lung cancer study for Kadmon's reversible tyrosine kinase inhibitor.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PNAS this week: miR-515 levels higher in women with preeclampsia, horizontal gene transfer in parasitic plants, and more.

A cancer researcher retracts 19 articles from one journal for image manipulation, according to Retraction Watch.

Precision medicine has to consider context in addition to genetic mutations in cancer treatment, Medscape reports.

Genomics may help the Cavendish banana from succumbing to fungal infections, a trio of researchers writes at the Conversation.